NanoViricides, Inc. (NASDAQ:NNVC) | WebDisclosure

Basculer en Français

9480	Companies
185564	Keywords
117971	Articles
99400	Press releases

Home
Companies
NanoViricides, Inc.

PRESS RELEASE

published on 09/30/2024 at 12:30, 1 year 2 months ago

NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID
NanoViricides, Inc. reports filing of Annual Report on Form 10-K for fiscal year 2024, financial updates, and plans for Phase II clinical trials of antiviral drug NV-387

NanoViricides NV-387 Financial Updates Form 10-K Phase II Clinical Trials
BRIEF

published on 09/26/2024 at 12:35, 1 year 2 months ago

NanoViricides Signs Comprehensive Antiviral Drug Agreement With TheraCour Pharma

NanoViricides NV-387 Antiviral Drugs TheraCour Pharma Trojan Horse Drugs
BRIEF

published on 09/26/2024 at 12:35, 1 year 2 months ago

NanoViricides signe un accord global sur les médicaments antiviraux avec TheraCour Pharma

NanoViricides NV-387 Médicaments Antiviraux TheraCour Pharma Drogues Du Type Cheval De Troie
PRESS RELEASE

published on 09/26/2024 at 12:30, 1 year 2 months ago

NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including “Trojan Horse” Drugs
NanoViricides, Inc. obtains right of first refusal for antiviral drug developments from TheraCour Pharma, expands drug portfolio with new MOU and revolutionary nanoviricide technology, including NV-387 for multiple viral infections

NV-387 Antiviral Drugs NanoViricides Inc. TheraCour Pharma Nanoviricide Technology
BRIEF

published on 08/26/2024 at 13:35, 1 year 3 months ago

NanoViricides Investigates NV-387 for MPOX Treatment Under WHO's MEURI Protocol

NanoViricides NV-387 Mpox WHO MEURI Protocol
BRIEF

published on 08/26/2024 at 13:35, 1 year 3 months ago

NanoViricides étudie le NV-387 pour le traitement du MPOX dans le cadre du protocole MEURI de l'OMS

NanoViricides NV-387 Mpox Protocole MEURI OMS
PRESS RELEASE

published on 08/26/2024 at 13:30, 1 year 3 months ago

MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX
NanoViricides, Inc. reports investigating NV-387 for MPOX treatment under WHO MEURI protocol amidst 2024 outbreak. NV-387 shows promise in animal studies for broad-spectrum antiviral use

NanoViricides NV-387 Broad-spectrum Antiviral MPOX Treatment WHO MEURI Protocol
BRIEF

published on 08/19/2024 at 12:35, 1 year 3 months ago

NanoViricides Advances Towards Phase II Trial of NV-387

NanoViricides NV-387 Antiviral Therapy Phase II Trial RSV, COVID, Influenza
BRIEF

published on 08/19/2024 at 12:35, 1 year 3 months ago

NanoViricides avance vers la phase II de l'essai du NV-387

NanoViricides NV-387 Essai De Phase II Thérapie Antivirale VRS, COVID, Grippe
PRESS RELEASE

published on 08/19/2024 at 12:30, 1 year 3 months ago

NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 - A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections
NanoViricides, Inc. provides update on Phase II clinical trial plans for broad-spectrum antiviral drug candidate NV-387 against RSV, COVID, and Influenza. Potential $12 Billion market. Novel trial design expected

NanoViricides NV-387 Clinical Trial Antiviral Phase II

Accesswire

Published on 12/06/2025 at 02:00, 17 minutes ago

Northern Dynasty Provides Update on Board Search and Audit & Risk Committee Composition
Published on 12/06/2025 at 01:15, 1 hour 2 minutes ago

Prospect Ridge Announces Closing of Flow-Through Unit Private Placement
Published on 12/06/2025 at 00:25, 1 hour 52 minutes ago

GMV Minerals Announces Non-Brokered Private Placement Pursuant to the Listed Issuer Financing Exemption
Published on 12/06/2025 at 00:00, 2 hours 17 minutes ago

Bird River Announces Closing of $0.10 Common Share Financing
Published on 12/05/2025 at 23:30, 2 hours 47 minutes ago

55 North Mining Inc. Announces Completion of Third and Final Tranche of Private Placement for a Total of $4,202,000

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 22:15, 4 hours 2 minutes ago

CPI PROPERTY GROUP - Changes in Shareholding and Board of Directors
Published on 12/05/2025 at 22:12, 4 hours 5 minutes ago

EQS-Adhoc: CPI PROPERTY GROUP - Change to Distribution Policy
Published on 12/05/2025 at 18:58, 7 hours 19 minutes ago

EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:26, 7 hours 51 minutes ago

POS-Transaction in Own Shares
Published on 12/05/2025 at 18:15, 8 hours 2 minutes ago

Completion of merger to form Helvetia Baloise Holding Ltd

Les Echos

Published on 12/05/2025 at 23:00, 3 hours 17 minutes ago

ALTAREIT : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 12/05/2025 at 23:00, 3 hours 17 minutes ago

ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 12/05/2025 at 23:00, 3 hours 17 minutes ago

ALTAREA : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES NOVEMBRE 2025
Published on 12/05/2025 at 23:00, 3 hours 17 minutes ago

ALTAREIT : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES NOVEMBRE 2025
Published on 12/05/2025 at 17:18, 8 hours 59 minutes ago

La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible

View all LES ECHOS COMFI WIRE